{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:23:07Z","timestamp":1778617387863,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2013KYA107"],"award-info":[{"award-number":["2013KYA107"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY1051"],"award-info":[{"award-number":["2022KY1051"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170502"],"award-info":[{"award-number":["81170502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81300400"],"award-info":[{"award-number":["81300400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.neo.2024.101084","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:32:22Z","timestamp":1732091542000},"page":"101084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Engineering and characterization of Hu3A4: A novel humanized antibody with potential as a therapeutic agent against myeloid lineage leukemias"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4862-8740","authenticated-orcid":false,"given":"Sisi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhujun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1409-5517","authenticated-orcid":false,"given":"Yongmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neo.2024.101084_bib0001","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.neo.2024.101084_bib0002","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036251","article-title":"Targeting immunophenotypic markers on leukemic stem cells: how lessons from current approaches and advances in the leukemia stem cell (LSC) model can inform better strategies for treating acute myeloid leukemia (AML)","volume":"10","author":"Mitchell","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.neo.2024.101084_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010253","article-title":"Present and future role of immune targets in acute myeloid leukemia","volume":"15","author":"Damiani","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2024.101084_bib0004","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1600-065X.1998.tb01441.x","article-title":"The roles of antibody variable region hypermutation and selection in the development of the memory B-cell compartment","volume":"162","author":"Manser","year":"1998","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.neo.2024.101084_bib0005","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/nbt1126","article-title":"Selecting and screening recombinant antibody libraries","volume":"23","author":"Hoogenboom","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neo.2024.101084_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106639","article-title":"Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives","volume":"85","author":"Parray","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.neo.2024.101084_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103415","article-title":"Monoclonal antibodies: Trends in therapeutic success and commercial focus","volume":"28","author":"Kinch","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"119","key":"10.1016\/j.neo.2024.101084_bib0008","doi-asserted-by":"crossref","DOI":"10.3791\/54832","article-title":"Generation of murine monoclonal antibodies by hybridoma technology","author":"Holzlohner","year":"2017","journal-title":"J. Vis. Exp."},{"issue":"7","key":"10.1016\/j.neo.2024.101084_bib0009","first-page":"13","article-title":"Molecular insights into fully human and humanized monoclonal antibodies: what are the differences and should dermatologists care?","volume":"9","author":"Mallbris","year":"2016","journal-title":"J. Clin. Aesthet Dermatol."},{"key":"10.1016\/j.neo.2024.101084_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.copbio.2019.01.012","article-title":"Why recombinant antibodies - benefits and applications","volume":"60","author":"Basu","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"issue":"6","key":"10.1016\/j.neo.2024.101084_bib0011","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14728222.2022.2083957","article-title":"Acute myeloid leukemia: therapeutic targeting of stem cells","volume":"26","author":"Pabon","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.neo.2024.101084_bib0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.13941","article-title":"CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia","volume":"173","author":"Kersten","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.neo.2024.101084_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.730899","article-title":"Stem cells in myelodysplastic syndromes and acute myeloid leukemia: first cousins or unrelated entities?","volume":"11","author":"Joudinaud","year":"2021","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.neo.2024.101084_bib0014","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/1061186X.2011.572973","article-title":"3A4, a new potential target for B and myeloid lineage leukemias","volume":"19","author":"Li","year":"2011","journal-title":"J. Drug Target"},{"issue":"9","key":"10.1016\/j.neo.2024.101084_bib0015","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1089\/dna.2018.4199","article-title":"Construction, expression, and characterization of a novel human-mouse chimeric antibody, Hm3A4: a potential therapeutic agent for B and myeloid lineage leukemias","volume":"37","author":"Li","year":"2018","journal-title":"DNA Cell Biol."},{"issue":"4","key":"10.1016\/j.neo.2024.101084_bib0016","doi-asserted-by":"crossref","first-page":"8631","DOI":"10.1080\/21655979.2022.2054159","article-title":"Potent anti-tumor activity of CD45RA-targeting Hm3A4-Ranpirnase against myeloid lineage leukemias","volume":"13","author":"Li","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.neo.2024.101084_bib0017","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-61779-974-7_13","article-title":"Humanization by CDR grafting and specificity-determining residue grafting","volume":"907","author":"Kim","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"2","key":"10.1016\/j.neo.2024.101084_bib0018","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0022-2836(92)91010-M","article-title":"Antibody framework residues affecting the conformation of the hypervariable loops","volume":"224","author":"Foote","year":"1992","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.neo.2024.101084_bib0019","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jmb.2007.02.100","article-title":"Analyzing the \"degree of humanness\" of antibody sequences","volume":"369","author":"Abhinandan","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neo.2024.101084_bib0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-61779-931-0_14","article-title":"Cloning, expression, and purification of monoclonal antibodies in scFv-Fc format","volume":"901","author":"Yang","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"17","key":"10.1016\/j.neo.2024.101084_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174206","article-title":"Single-chain fragment variable: recent progress in cancer diagnosis and therapy","volume":"14","author":"Munoz-Lopez","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.neo.2024.101084_bib0022","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/21645515.2017.1407482","article-title":"Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells","volume":"14","author":"Banisadr","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.neo.2024.101084_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2020.112868","article-title":"Development of a SARS-CoV-2-specific biosensor for antigen detection using scFv-Fc fusion proteins","volume":"175","author":"Kim","year":"2021","journal-title":"Biosens. Bioelectron."},{"issue":"4","key":"10.1016\/j.neo.2024.101084_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01934-21","article-title":"Single-chain variable fragments of broadly neutralizing antibodies prevent HIV cell-cell transmission","volume":"96","author":"van Dorsten","year":"2022","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.neo.2024.101084_bib0025","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1158\/1541-7786.MCR-16-0136","article-title":"High-affinity internalizing human scFv-Fc antibody for targeting FGFR1-overexpressing lung cancer","volume":"15","author":"Sokolowska-Wedzina","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.neo.2024.101084_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192194","article-title":"Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers","volume":"13","author":"Borek","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.neo.2024.101084_bib0027","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1096\/fj.201701544R","article-title":"Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies","volume":"32","author":"Sioud","year":"2018","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.neo.2024.101084_bib0028","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12885-021-08056-4","article-title":"RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480","volume":"21","author":"Huang","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.neo.2024.101084_bib0029","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/JVI.05848-11","article-title":"Single-chain Fv-based anti-HIV proteins: potential and limitations","volume":"86","author":"West","year":"2012","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.neo.2024.101084_bib0030","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1038\/s41598-022-09324-4","article-title":"Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv","volume":"12","author":"Arslan","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neo.2024.101084_bib0031","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2163784","article-title":"Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease","volume":"12","author":"Shrestha","year":"2023","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.neo.2024.101084_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12103041","article-title":"Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies","volume":"12","author":"van der Horst","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2024.101084_bib0033","first-page":"7","article-title":"Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC","volume":"3","author":"Natsume","year":"2009","journal-title":"Drug Des. Devel. Ther.,"},{"issue":"1","key":"10.1016\/j.neo.2024.101084_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007135","article-title":"A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer","volume":"12","author":"Desroys du Roure","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.neo.2024.101084_bib0035","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.101084_bib0036","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023023370","article-title":"T cell help in the tumor microenvironment enhances rituximab-mediated NK cell ADCC","author":"Arora","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.101084_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1083462","article-title":"Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.neo.2024.101084_bib0038","article-title":"Enhancing CDC and ADCC of CD19 antibodies by combining Fc protein-engineering with Fc glyco-engineering","volume":"9","author":"Rosskopf","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"1-2","key":"10.1016\/j.neo.2024.101084_bib0039","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jim.2011.08.003","article-title":"Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC","volume":"373","author":"Repp","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.neo.2024.101084_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pep.2013.10.017","article-title":"Successful construction and stable expression of an anti-CD45RA scFv-EGFP fusion protein in Chinese hamster ovary cells","volume":"94","author":"Wang","year":"2014","journal-title":"Protein Expr. Purif."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624001258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624001258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:00:46Z","timestamp":1778616046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558624001258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"alternative-id":["S1476558624001258"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2024.101084","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering and characterization of Hu3A4: A novel humanized antibody with potential as a therapeutic agent against myeloid lineage leukemias","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2024.101084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101084"}}